I did not mention that one should or should not be comfortable. It is personal choice and it comes with understanding & conviction. I wanted to know the personal comfort level of someone who holds 30% exposure to HDFC group.
If you ask my personal comfort level - If a diversified FMCG firm reaches 30% of my portfolio, I might be a little more granular with its moves and on greater watch. If it is an MNC such as HUL/Nestle maybe less concerned but if it is an Indian MNC then more on the watchout.
If a Finance lending business reached 30% - I would not allow that anymore. Have learnt it hard way of never to trust a lender, specially NBFC and only bank I can dare to hold is an HDFC.
If a Finance group reaches 30% of my portfolio - I will be nervous and may trim it to 20-25% max. Maybe trade the remaining 5%.
Now coming to your question on why to have this thought - We have seen many big and respectable groups falter. In this amazing stock market which gives us so much opportunity, it will be a pity if we fall down along with any such esteemed group.
I have currently 20% exposure to Tata group and 20% to HDFC group…so almost half of my portfolio depends on these two groups. I cannot remove this thought from my mind and let my guard down. Although, if any faltering happens, we retail investors would be last to know and most damage would already be done.
Having said above, RJ has almost all his net worth in one group thats Tata…and that too a single company - Titan. Compared to Titan, no other company in his portfolio matters anything…
Tata and HDFC are indeed most trustworthy management…not sure if my comfort level today are fine and as I myself have no clear answer hence seek what others feel to learn and grow my own thought process around it…
What are your thoughts on this knowing how big and respectable groups around the world have time and again gone into big troubles?
4 Likes
I think if we combine our views the net solution comes out to be sensibly diversified in a sector .
But still are we ready to go for suppose a kotak bank instead of a hdfc bank if we already have 2 or more hdfc stocks in portfolio ? Of course, big groups have fallen time and time again and it’s always the retail investors who have cried blood tears.
I guess this theory has no clear answer and one should go his own way depending on one’s investing style , type of view and comfort level.
Thanks for your insight.
1 Like
March 2021 Monthly Portfolio Updates
Direct Equity Portfolio Allocation
| S.No |
Stock Name |
Inspired From |
Alloc% |
Comments |
| 1 |
ABBOTINDIA |
@MarcellusInvest |
7.00% |
Leader in Branded Medicine |
| 2 |
ASIANPAINT |
@MarcellusInvest |
7.00% |
Leader in Paints |
| 3 |
BIOCON |
@unseenvalue |
7.00% |
Leader in Biologics Pharam. |
| 4 |
CUPID |
@Coolfundoo |
1.67% |
Leader in Condom manufacturing |
| 5 |
DIVISLAB |
@MarcellusInvest |
7.00% |
Leader in API manufacturing, |
| 6 |
FINEORG |
@MarcellusInvest |
3.33% |
Leader in Food additives |
| 7 |
GODREJAGRO |
@Coolfundoo |
3.33% |
Leader in animal feed |
| 8 |
HDFC |
@MarcellusInvest |
7.00% |
Leader in Home loans financing, |
| 9 |
HDFCAMC |
@MarcellusInvest |
7.00% |
Leader in Asset Management. |
| 10 |
HDFCBANK |
@MarcellusInvest |
7.00% |
Leader in Pvt Bank, |
| 11 |
HDFCLIFE |
@MarcellusInvest |
7.00% |
Leader in Pvt Insurance business. |
| 12 |
HIKAL |
@unseenvalue |
1.66% |
Diversified business including pharma and checmical |
| 13 |
ITC |
@dmuthuk |
7.00% |
Leader in Cigarattes, |
| 14 |
NESTLEIND |
@MarcellusInvest |
7.00% |
Leader in food and beverages |
| 15 |
PIDILITIND |
@MarcellusInvest |
7.00% |
Leader in adheseives, |
| 16 |
SYNGENE |
@unseenvalue |
3.34% |
Leader in Biologics API manufactuirng & CRAMS |
| 17 |
TCS |
@MarcellusInvest |
8.00% |
Leader in IT, |
| 18 |
TRANSPEK |
@safiranand |
1.67% |
Leader in Chlorine chemistry |
New Stock Additions
Hikal, Transpek, Fine Organics and Cupid. - Small cap stocks with decent valuation
Portfolio Stock Deletions
None
Cash Position 1%
Snapshot of my holding
Stocks in watchlist:
None
2 Likes
Very nice portfolio !! I like 60% of your 
holdings ( rest I have not researched enough , but those must be equally good too ) !!!
1 Like
@Malai_Subramanian Hi, how do you know/keep track as to when these investors are reducing/selling their holdings?
1 Like
Most of these are Coffee Can stock, year after year, it doesn’t matter much if those investor sell too as long as these companies are fulfilling the criteria of good sales growth, high ROCE.
1 Like
As @Sandeep_Verma mentioned I would like to hold on to these business until the fundamentals are good/improving like posting good sales growth, profit growth, high ROCE and high ROE.
1 Like
April 2021 Monthly Portfolio Updates
Direct Equity Portfolio Allocation
| S.No |
Stock Name |
Inspired From |
Alloc% |
Comments |
| 1 |
ABBOTINDIA |
@MarcellusInvest |
7.71% |
Leader in Branded Medicine |
| 2 |
ASIANPAINT |
@MarcellusInvest |
7.71% |
Leader in Paints |
| 3 |
BIOCON |
@unseenvalue |
7.00% |
Leader in Biologics Pharam. |
| 4 |
DIVISLAB |
@MarcellusInvest |
7.00% |
Leader in API manufacturing, |
| 5 |
HDFC |
@MarcellusInvest |
7.71% |
Leader in Home loans financing, |
| 6 |
HDFCAMC |
@MarcellusInvest |
7.50% |
Leader in Asset Management. |
| 7 |
HDFCBANK |
@MarcellusInvest |
7.71% |
Leader in Pvt Bank, |
| 8 |
HDFCLIFE |
@MarcellusInvest |
7.00% |
Leader in Pvt Insurance business. |
| 9 |
ITC |
@dmuthuk |
7.50% |
Leader in Cigarattes, |
| 10 |
NESTLEIND |
@MarcellusInvest |
7.71% |
Leader in food and beverages |
| 11 |
PIDILITIND |
@MarcellusInvest |
7.71% |
Leader in adheseives, |
| 12 |
SYNGENE |
@unseenvalue |
7.00% |
Leader in Biologics API manufactuirng & CRAMS |
| 13 |
TCS |
@MarcellusInvest |
10.02% |
Leader in IT, |
New Stock Additions
None
Portfolio Stock Deletions
Godrej Agrovet, Hikal, Transpek, Fine Organics and Cupid. - Exit due to low conviction and risk due to covid second wave.
Cash Position 1%
Snapshot of my holding
Stocks in watchlist:
None
3 Likes
May 2021 Monthly Portfolio Updates
Direct Equity Portfolio Allocation
| S.No |
Stock Name |
Inspired From |
Alloc% |
Comments |
| 1 |
ABBOTINDIA |
@MarcellusInvest |
7.71% |
Leader in Branded Medicine |
| 2 |
ASIANPAINT |
@MarcellusInvest |
7.71% |
Leader in Paints |
| 3 |
BIOCON |
@unseenvalue |
7.00% |
Leader in Biologics Pharam. |
| 4 |
DIVISLAB |
@MarcellusInvest |
7.00% |
Leader in API manufacturing, |
| 5 |
HDFC |
@MarcellusInvest |
7.71% |
Leader in Home loans financing, |
| 6 |
HDFCAMC |
@MarcellusInvest |
7.50% |
Leader in Asset Management. |
| 7 |
HDFCBANK |
@MarcellusInvest |
7.71% |
Leader in Pvt Bank, |
| 8 |
HDFCLIFE |
@MarcellusInvest |
7.00% |
Leader in Pvt Insurance business. |
| 9 |
ITC |
@dmuthuk |
7.50% |
Leader in Cigarattes, |
| 10 |
NESTLEIND |
@MarcellusInvest |
7.71% |
Leader in food and beverages |
| 11 |
PIDILITIND |
@MarcellusInvest |
7.71% |
Leader in adheseives, |
| 12 |
SYNGENE |
@unseenvalue |
7.00% |
Leader in Biologics API manufactuirng & CRAMS |
| 13 |
TCS |
@MarcellusInvest |
10.02% |
Leader in IT, |
New Stock Additions
None
Portfolio Stock Deletions
10% of all stocks sold to add to Malai’s Copy Cat Portfolio #2
Cash Position 0%
Snapshot of my holding
Stocks in watchlist:
None
2 Likes
Very methodical approach. I like the idea of 10 to 15 stocks with cap on 20%. However, your investments are equally weighted. It seems you are rebalancing them regularly so Market cap doesn’t influence your dollar return. I have only one comment on risk perspective. Your exposure to the HDFC group is around 30%. I mean you may think of limiting group level exposure to 20%. Would you like to pick a non-HDFC stock with similar characteristics in the sector. Any negative news for the group may impact others. Overall, looks good All the best. Please keep sharing.
1 Like
Thanks for your feedback on my Portfolio.
- Will look into reducing the exposure to HDFC group.
- I don’t re balance, the allocation is calculated based on the invested amount not the current amount.
1 Like
I feel its okay as all companies are independent and under different management, HDFC group companies are under professional management and one benefit of having HDFC companies is that they get business from each other, which provides MOAT over other institution)(s), no other group has such network presence as HDFC group companies.
1 Like
June 2021 Monthly Portfolio Updates
Direct Equity Portfolio Allocation
| S.No |
Stock Name |
Market Cap |
Portfolio |
Inspired From |
Industry |
Allocation |
Comments |
| 1 |
ASIANPAINT |
Largecap |
Core |
@MarcellusInvest |
Materials |
5.15 |
Leader in Paints |
| 2 |
BAJAJFINSERV |
Largecap |
Core |
@ Coolfundoo |
Financials |
4.53 |
Leader in NBFC |
| 3 |
BIOCON |
Largecap |
Growth |
@unseenvalue |
Healthcare |
4.69 |
Leader in Biologics |
| 4 |
DEEPAKNTR |
Largecap |
Growth |
@soicfinance |
Materials |
4.84 |
Leader in Phenol Chemistry |
| 5 |
DIVISLAB |
Largecap |
Core |
@MarcellusInvest |
Healthcare |
5.27 |
Leader in API |
| 6 |
GODREGAGRO |
Midcap |
Growth |
@ Coolfundoo |
Consumer Staples |
3.68 |
Leader in feeds, Crop Protection, Dairy, etc |
| 7 |
HCG |
Smallcap |
Growth |
@unseenvalue |
Healthcare |
2.71 |
Leader in Oncology Hospital |
| 8 |
HDFC |
Largecap |
Core |
@MarcellusInvest |
Financials |
4.9 |
Leader in home finance |
| 9 |
HDFCLIFE |
Largecap |
Core |
@dmuthuk |
Financials |
4.78 |
Leader in Life Insurance |
| 10 |
IEX |
Midcap |
Growth |
@soicfinance |
IT |
3.88 |
Leader in Power exchanges |
| 11 |
INTELLECT |
Smallcap |
Growth |
@ sahil_vi |
IT |
1.98 |
Leader in Banking software |
| 12 |
ITC |
Largecap |
Value |
@dmuthuk |
Consumer Staples |
4.75 |
Leader in Cigarettes |
| 13 |
JUBLPHARMA |
Smallcap |
Growth |
@unseenvalue |
Healthcare |
2.81 |
Leader in Radiopharma API and other CDMO |
| 14 |
KOTAKBANK |
Largecap |
Core |
@MarcellusInvest |
Financials |
4.78 |
Leader in Retail banking |
| 15 |
LAURUSLABS |
Largecap |
Growth |
@soicfinance |
Healthcare |
4.55 |
Leader in ARV API and biosimilar |
| 16 |
LTTS |
Largecap |
Growth |
@ Coolfundoo |
IT |
4.46 |
Leader in ERD services |
| 17 |
NESTLEIND |
Largecap |
Core |
@dmuthuk |
Consumer Staples |
4.9 |
Leader in food and beverages |
| 18 |
PIDILITIND |
Largecap |
Core |
@dmuthuk |
Materials |
4.9 |
Leader in adhesives |
| 19 |
PRAJIND |
Smallcap |
Growth |
@unseenvalue |
Materials |
3.1 |
Leader in Industrial Biotechnology |
| 20 |
RALLIS |
Midcap |
Growth |
@unseenvalue |
Materials |
3.68 |
Leader in Pesticides and Bio Pesticides |
| 21 |
SEQUENT |
Midcap |
Growth |
@soicfinance |
Healthcare |
3.97 |
Leader in Animal pharma API |
| 22 |
TCS |
Largecap |
Core |
@MarcellusInvest |
IT |
5.39 |
Leader in IT |
| 23 |
TITAN |
Largecap |
Core |
@dmuthuk |
Consumer Discretionary |
4.41 |
Leader in jewelry |
| 24 |
VAIBHAVGBL |
Smallcap |
Growth |
@ sahil_vi |
Consumer Discretionary |
1.94 |
Leader in low cost jewelry |
New Stock Additions
From Satellite portfolio:
- DEEPAKNTR
- GODREGAGRO (Indirectly owning Astec Lifesiciences)
- HCG
- IEX
- JUBLPHARMA
- LAURUSLAB
- LTTS
- PRAJIND
- RALLIS
- SEQUENT
Fresh addition:
- Vaibhav Global
- Intellect Design Arena
- Kotak Bank
- Bajaj Finserv
- Titan
Portfolio Stock Deletions
- HDFC Bank (Indirectly owning by HDFC Ltd)
- HDFC AMC (Indirectly owning by HDFC Ltd)
- Abbot India
- Syngene (Indirectly owning by Biocon)
Cash Position 0%
Snapshot of my holding
Sector Allocation:
| Sector |
% |
| Consumer Staples |
13.33% |
| Financials |
18.99% |
| Healthcare |
24.01% |
| Materials |
21.67% |
| IT |
15.66% |
| Consumer Discreatonary |
6.35% |
Market Cap Allocation:
| Marketcap |
% |
| Largecap |
72.29% |
| Midcap |
15.21% |
| Smallcap |
12.50% |
Strategy Allocation:
| Category |
% |
| Core |
49.00% |
| Growth |
46.25% |
| Value |
4.75% |
Inspiration Allocation:
| Category |
% |
| @MarcellusInvest |
25.48% |
| @dmuthuk |
23.74% |
| @unseenvalue |
17.37% |
| @soicfinance |
16.97% |
| @ Coolfundoo |
12.46% |
| @ sahil_vi |
03.98% |
Stocks in watchlist:
Neuland Labs
Amrutanjan
Racl
Jubiliant Ingrevia
3 Likes
Your investment rationale column has gotten erroneous. Please fix it. Each Stock’s rationale has gotten shifted up.
And, what is the reason behind quitting Abbott Labs?
2 Likes
I fixed the column, thanks for pointing it out.
Major reason for selling the Abbot India is due to the poor disclosures like unavailability of conference call, quarterly presentation/management commentary, etc. Basically I could not understand what is there plan for the future except through their annual report. Meanwhile they do have a good products under their belt.
Also I find good opportunity in CDMO/CRAMS space as they have huge tailwind, capex, guidance, etc.
Hope I answer your question.
2 Likes
I have never even read about this company 
Thanks for the VGL tag.
Yes I agree, this is indirectly inspired from the Mastek thread 
2 Likes
Not a stock recommendation but a “guru” recommendation. You can check out Shahshank Udupa on YouTube and vikas_sinha on valuepickr. Have been following them for some time as I have a similar approach to investing as you.
1 Like
July 2021 Monthly Portfolio Updates
Note: There is a lot of changes in the grouping done i.e the stock are allocated better category for each group like Market Cap, Inspired From and Portfolio based on various parameters. Hence you will find changed from last month update.
Direct Equity Portfolio Allocation
| S.No |
Stock Name |
Market Cap |
Portfolio |
Inspired From |
Industry |
Stock Alloc |
Comments |
| 1 |
AFFLE |
Midcap |
Growth |
@ Coolfundoo |
IT |
4.00% |
Leader in Mobile Advertising |
| 2 |
AMRUTANJAN |
Smallcap |
Value |
@MarcellusInvest |
Consumer Staples |
3.00% |
Leader in Pain relief |
| 3 |
APLLTD |
Midcap |
Value |
@ Malkd |
Healthcare |
4.00% |
Leader in Pharma formulation |
| 4 |
ASIANPAINT |
Largecap |
Core |
@MarcellusInvest |
Materials |
5.00% |
Leader in Paints |
| 5 |
BAJAJFINSV |
Largecap |
Core |
@ Coolfundoo |
Financials |
5.00% |
Leader in NBFC |
| 6 |
BIOCON |
Midcap |
Value |
@unseenvalue |
Healthcare |
4.00% |
Leader in Biologics |
| 7 |
DEEPAKNTR |
Midcap |
Growth |
@soicfinance |
Materials |
4.00% |
Leader in Pheonol Chemistry |
| 8 |
DIVISLAB |
Largecap |
Core |
@MarcellusInvest |
Healthcare |
5.00% |
Leader in Generic API |
| 9 |
GODREJAGRO |
Midcap |
Value |
@ Coolfundoo |
Consumer Staples |
4.00% |
Leader in Animal feeds, Crop Protection, Dairy, etc |
| 10 |
HCG |
Smallcap |
Growth |
@unseenvalue |
Healthcare |
3.00% |
Leader in Oncology Hospital |
| 11 |
HCLTECH |
Largecap |
Core |
@ Coolfundoo |
IT |
5.00% |
Leader in IT services |
| 12 |
HDFC |
Largecap |
Value |
@dmuthuk |
Financials |
5.00% |
Leader in home finance |
| 13 |
IEX |
Midcap |
Growth |
@soicfinance |
IT |
4.00% |
Leader in Power exchanges |
| 14 |
INTELLECT |
Smallcap |
Growth |
@ Malkd |
IT |
3.00% |
Leader in Banking software |
| 15 |
ITC |
Largecap |
Value |
@dmuthuk |
Consumer Staples |
5.00% |
Leader in Cigarettes |
| 16 |
JUBLPHARMA |
Smallcap |
Value |
@unseenvalue |
Healthcare |
3.00% |
Leader in Radiopharma API and other CDMO |
| 17 |
KOTAKBANK |
Largecap |
Value |
@MarcellusInvest |
Financials |
5.00% |
Leader in Retail banking |
| 18 |
LAURUSLABS |
Midcap |
Growth |
@soicfinance |
Healthcare |
4.00% |
Leader in ARV API and biosimilar |
| 19 |
LTTS |
Midcap |
Growth |
@ Coolfundoo |
IT |
4.00% |
Leader in ERD services |
| 20 |
NEULANDLAB |
Smallcap |
Growth |
@ sahil_vi |
Healthcare |
3.00% |
Leader in Peptides CRAMS |
| 21 |
PIDILITIND |
Largecap |
Core |
@dmuthuk |
Materials |
5.00% |
Leader in adhesives |
| 22 |
PRAJIND-BE |
Smallcap |
Growth |
@unseenvalue |
Materials |
3.00% |
Leader in Industrial Biotechnology |
| 23 |
RALLIS |
Smallcap |
Value |
@unseenvalue |
Materials |
3.00% |
Leader in Pesticides and Bio Pesticides |
| 24 |
SEQUENT |
Smallcap |
Growth |
@soicfinance |
Healthcare |
3.00% |
Leader in Animal pharma API |
| 25 |
VAIBHAVGBL |
Midcap |
Growth |
@ sahil_vi |
Consumer Discretionary |
4.00% |
Leader in low cost jwellery |
New Stock Additions
- Affle (Mobile marketing technology)
- Amrutanjan (Niche business)
- Alembic Pharma (Good business available at cheap valuation)
- HCL Technologies (Better Valuation compared to TCS)
Portfolio Stock Deletions
- HDFC Life (Owning through HDFC Ltd)
- Nestle India (High Valuation)
- TCS (High Valuation)
- Titan (High Valuation)
Cash Position 0%
Snapshot of my holding
Sector Allocation:
| Sector |
% |
| Consumer Staples |
12% |
| Financials |
15% |
| Healthcare |
29% |
| Materials |
20% |
| IT |
20% |
| Consumer Discreatonary |
4% |
Market Cap Allocation:
| Marketcap |
% |
| Largecap |
40% |
| Midcap |
36% |
| Smallcap |
24% |
Strategy Allocation:
| Category |
% |
| Core |
25% |
| Growth |
36% |
| Value |
39% |
Inspiration Allocation:
| Category |
% |
| @MarcellusInvest |
18% |
| @dmuthuk |
15% |
| @unseenvalue |
16% |
| @soicfinance |
15% |
| @ Coolfundoo |
22% |
| @ sahil_vi |
7% |
| @ Malkd |
7% |
Stocks in watchlist:
Jubiliant Ingrevia
Strides Pharma
3 Likes
Please look at valuations when we copy stocks from others portfolio . Are you comfortable paying 80 P/E for a sales /profit growth of 9 /13 % (Asian paints). Sequent/LTTS are all trading at high valuations . Please look at growth triggers , before copying , if you are paying such huge multiples.
Disc: I was holding LTTS but i sold out around 2900 due to high valuations(IMHO) .
I exited 90% of my Biocon holdings around 400 a year ago … Looking to reenter in a quarter or so .
2 Likes
